Lecithin cholesterol acyltransferase deficiency
WikiDoc Resources for Lecithin cholesterol acyltransferase deficiency
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
To view Lipoprotein Disorders Main Page Click here
To view Hypolipoproteinemia Main Page Click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D.  Associate Editor(s)-in-Chief: Aravind Kuchkuntla, M.B.B.S
Synonyms and keywords:LCAT deficiency, dyslipoproteinemic corneal dystrophy, fish eye disease, Norum disease, partial LCAT deficiency, Familial LCAT deficiency
Lecithin cholesterol acyltransferase (LCAT) is an enzyme with 2 subunits catalyzing the esterification of free cholesterol into cholesterol esters, an important step in the reverse cholesterol transport. LCAT deficiency is a monogenic autosomal recessive disease resulting from mutation in the LCAT gene on chromosome number 16. Patients with homozygous and compound heterozygous mutations are symptomatic due to the accumulation of excessive free cholesterol in the cornea, RBC cell membrane and the kidney. LCAT deficiency is classified into Familial LCAT deficiency(FLD) and Fish Eye Disease (FED) based on the degree of the enzyme function lost. The characteristic feature of these diseases is low plasma HDL C. FLD is a severe form with low HDL C and increase in LDL type protein called lipoprotein-X causing progressive renal failure, FED has a benign course with corneal opacities and low HDL C alone. Low HDL is a risk factor for development of cardiovascular disease,but the risk of developing atherosclerosis and cardiovascular disease in LCAT deficiency is still not well defined and is controversial.
- In 1962, Glomset identified an enzyme (plasma fatty acid transferase) which transfers fatty acid onto free cholesterol forming a cholesterol ester helping in the formation of a mature HDL particle, a crucial step of reverse cholesterol transport. 
- In 1967, Norum and Gjone described a disease for the first time in a patient from Norway with features of normochromic anemia, proteinuria and corneal lipid deposits.
- In 1967, Norum and Gjone reported two sisters of the affected patient had similar presentation along with low levels of cholesterol esters and lysolecithin in the serum, with increased total body cholesterol, triglyceride and phospholipid. Other additional findings included were :
- Foam cells were demonstrated in bone marrow and glomerulus on microscopy.
- Patients had absent hepatomegaly differentiating it from liver disease causing the defect in esterification.
- Patients had normal tonsils differentiating it from Tangier disease.
- Low serum cholesterol esters were attributed to the LCAT enzyme deficiency.
- In 1986, McLean and colleagues reported the complete gene sequence and the sites of expression on lecithin cholesterol acyl transferase gene (LCAT). The location of the gene is identified to be on q21-22 region of chromosome 16. 
LCAT deficiency is classified based on the quantity of enzyme function defective. A mutation in the LCAT gene can cause either a complete loss of function or a partial loss of function which is the basis of LCAT deficiency classification:
- Familial LCAT deficiency(FLD): Complete loss of alpha and beta LCAT function.
- Fish Eye Disease (FED): Loss of alpha LCAT function with preserved beta function.
|Familial LCAT deficiency (FLD)||Fish Eye Disease (FED)|
|Enzyme Function||Completely dysfunctional||Loss of alpha function only|
|Clinical Features||Corneal opacities, anaemia
and progressive renal disease with proteinuria
|Corneal opacities only;
Normal renal function
|Microscopy||Deposition of free cholesterol and phospholipids in cornea, RBC cell membrane and in the kidney||Deposition of free cholesterol and phospholipids in the cornea|
|Laboratory findings||Elevated free cholesterol||Elevated free cholesterol
HDL C < 27 mg/dL
|Electrophoresis||Pre β-1 and α-4 HDL, LDL C with β mobility due to||Pre β-1and α-4 HDL with normal
|Treatment||Preserve kidney function||Optimize lipid levels
Responds to statins
|LCAT is synthesized in liver and released into circulation and is picked up by HDL C|
|Apo A1 activates LCAT associated with HDL, Apo E activates LCAT associated with LDL C|
|LCAT cleaves fatty acid from phosphotidylcholine|
|Transfers fatty acid to beta hydroxyl group of free cholesterol taken up by HDL C|
|Results in the formation of cholesterol esters which help in maturation of HDL C and also forms lysophosphotidylcholine|
|Esterification of free cholesterol taken up by HDL C, is α-LCAT activity. Esterification of free cholesterol associated with Apo B( LDL C), is β-LCAT activity. This differentiation into alpha and beta is based on the HDL and LDL mobility on electrophoresis|
- Majority of the enzyme is associated with HDL C; only a very minor amount is associated with LDL C.
- LCAT helps in reverse cholesterol transport by:
|Loss of LCAT function|
|Loss of alpha function leads to failure of HDL maturation resulting in elevated FC, phospholipids, Apo E, pre beta HDL, and low Apo A1 and Apo A2 levels||Loss of beta function results in elevated FC, phospholipids, and formation of cholesterol rich multilamellar particles called Lipoprotein X , which are implicated in the development of glomerulopathy .|
LCAT deficiency presents the following genetic characteristics:
- LCAT deficiency is transmitted in a autosomal recessive inheritance.
- LCAT gene is located on chromosome 16, and multiple mutation sites have been identified.
- The expression of clinical features and severity of disease in homozygous patients is determined by the type and locus of the mutation.
- Heterozygous patients have an intermediate biochemical expression with reduced plasma HDLC and Apo A1 levels.
Microscopic and histopathological examinations of tissues in LCAT deficiency will reveal the following:
- Deposition of free cholesterol and phospholipids in the cornea and RBC membrane.
- Kidney biopsy in the early stage of the disease show mild mesangium enlargement and thickening of glomerular basement membrane (GBM).
- Sea blue histiocytes on Wright-Giemsa are observed in bone marrow and spleen.
Epidemiology and Demographics
- The prevalence of Familial LCAT deficiency rare and is estimated to be less than 1/1,000,000. About 125 cases have been reported to date worldwide.
- Majority of the cases are reported in Europe, Japan and Canada.
Natural History, Complications and Prognosis
- If left untreated, patients with FLD will develop progressive decline in renal function, resulting in end stage renal disease.
- Corneal opacities are the earliest manifestation and appear in early childhood; it usually starts at the limbus as an annular opacity resembling arcus lipoides senilis which is different from Tangier disease where it is more central and dense.Visual disturbances are not common.
- Hemolytic anemia results from excessive free cholesterol, phospholipid deposition, and increased phosphotidylcholine in the RBC membrane causing erythrocyte fragility.
- Renal disease is the major complication and begins in adolescence with proteinuria and progresses to end stage renal disease requiring hemodialysis or transplantation in the patient's 30's and 40's
- Mortality and morbidity of FLD is dependent on the progression of kidney disease and prognosis is poor.
- FED has a benign course.
History and Symptoms
- Corneal opacities in childhood
- Dyspnea on exertion
- Generalized body swelling
- Bloody urine
- Less common presenting features include:
- Abdominal discomfort
Physical examination of patients with LCAT deficiency is remarkable for the following:
- Bilateral annular corneal opacities, characteristic clinical manifestation of FLD and FED
- Hepatomegaly and splenomegaly
Laboratory findings consistent with the diagnosis of Familial LCAT deficiency include:
- Very low HDL C levels 
- High unesterified cholesterol(UC) to total cholesterol ratio (TC) is the characteristic laboratory finding.
- Low Apo A1 and Apo AII levels due to increased catabolism resulting from the failure in cholesterol ester formation, causing structural and composition changes in HDL C particles.
- LDL C in these patients displays a characteristic morphology with large LDL C particles containing high levels of free cholesterol, phospholipids and low cholesterol ester content.
- Urinalysis show nephrotic range proteinuria.
2D gel electrophoresis in FLD is remarkable for the following:
- Homozygotes have Apo A1 in plasma present only in preβ-1 and α-4 discoidal HDL particles after Apo A1 immunoblotting.
- Heterozygotes for LCAT deficiency have less than 50% of normal large alpha-1 HDL, but two-fold increases in very small beta-1 HDL C.
- Elevation in free cholesterol-enriched LDLhCaving β betanmobility stead of pre β mobility.
- Two-dimensional gel electrophoresis after immunoblotting with specific antibody for Apo A1 helps differentiate between homozygous Apo A1 deficiency, ABCA1 deficiency and LCAT deficiency.
Low HDL C differential diagnosis
|Apo A1 Deficiency|
|Gene Defect||LCAT||LCAT||ABCA1||ABCA1||Apo A1|
|Inheritance||Autosomal Recessive||Autosomal Recessive||Autosomal Recessive||Autosomal Recessive||Autosomal Dominant|
||Loss of alpha function only||
Pre beta-1 HDL fails to picks up free cholesterol from cells due to mutation in ABCA1 transporter.
|Similar to homozygous||Defective synthesis of Apo A1 resulting in failure of maturation of HDL and defective reverse cholesterol transport.|
|2D Gel Electrophoresis||Pre β-1 and α-4 HDL, LDL with β mobility due to Lipoprotien-X||Pre β-1and α-4 HDL with normal pre-β LDL.||Only preβ-1 HDL present||
||Lack of Apo A1 containing HDL particles.|
The mainstay of therapy for Familial LCAT deficiency include:
- Preserving kidney function
- Controlling hypertension
While there is no definitive medical therapy to treat LCAT deficiency, the following methods can help mitigate complications and alleviate symptoms:
- Recombinant human LCAT enzyme replacement has shown to improve anemia and HDL C levels and to preserve kidney function. 
- Currently it is at the manufacturing stage and is not yet available for widespread use.
- High dose angiotensin receptor blockers help in improving blood pressure, proteinuria and kidney function.
- Patients dependent on hemodialysis with worsening renal function are indicated for renal transplant.
- Lipid abnormalities usually recur after a renal transplant .
- There are no screening recommendations for the disease. Patients are advised regular follow up, medication compliance and monitoring of the renal function to prevent progressive decline in renal function.
- Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R; et al. (2014). "2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S49–73. doi:10.1161/01.cir.0000437741.48606.98. PMID 24222018.
- Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C; et al. (2009). "Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans". Circulation. 120 (7): 628–35. doi:10.1161/CIRCULATIONAHA.108.818143. PMID 19687369.
- Ossoli A, Simonelli S, Vitali C, Franceschini G, Calabresi L (2016). "Role of LCAT in Atherosclerosis". J Atheroscler Thromb. 23 (2): 119–27. doi:10.5551/jat.32854. PMID 26607351.
- GLOMSET JA (1962). "The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase". Biochim Biophys Acta. 65: 128–35. PMID 13948499.
- Norum KR, Gjone E (1967). "Familial serum-cholesterol esterification failure. A new inborn error of metabolism". Biochim Biophys Acta. 144 (3): 698–700. PMID 6078131.
- Gjone E, Norum KR (1968). "Familial serum cholesterol ester deficiency. Clinical study of a patient with a new syndrome". Acta Med Scand. 183 (1–2): 107–12. PMID 5669813.
- McLean J, Wion K, Drayna D, Fielding C, Lawn R (1986). "Human lecithin-cholesterol acyltransferase gene: complete gene sequence and sites of expression". Nucleic Acids Res. 14 (23): 9397–406. PMC 311966. PMID 3797244.
- McIntyre N (1988). "Familial LCAT deficiency and fish-eye disease". J Inherit Metab Dis. 11 Suppl 1: 45–56. PMID 3141686.
- Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, Droste C; et al. (1991). "A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity". Proc Natl Acad Sci U S A. 88 (11): 4855–9. PMC 51765. PMID 2052566.
- Dimick SM, Sallee B, Asztalos BF, Pritchard PH, Frohlich J, Schaefer EJ (2014). "A kindred with fish eye disease, corneal opacities, marked high-density lipoprotein deficiency, and statin therapy". J Clin Lipidol. 8 (2): 223–30. doi:10.1016/j.jacl.2013.11.005. PMID 24636183.
- Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G; et al. (2007). "Role of LCAT in HDL remodeling: investigation of LCAT deficiency states". J Lipid Res. 48 (3): 592–9. doi:10.1194/jlr.M600403-JLR200. PMID 17183024.
- Chen CH, Albers JJ (1982). "Distribution of lecithin-cholesterol acyltransferase (LCAT) in human plasma lipoprotein fractions. Evidence for the association of active LCAT with low density lipoproteins". Biochem Biophys Res Commun. 107 (3): 1091–6. PMID 7138515.
- Tall AR (1990). "Plasma high density lipoproteins. Metabolism and relationship to atherogenesis". J Clin Invest. 86 (2): 379–84. doi:10.1172/JCI114722. PMC 296738. PMID 2200802.
- Narayanan S (1984). "Biochemistry and clinical relevance of lipoprotein X." Ann Clin Lab Sci. 14 (5): 371–4. PMID 6476782.
- Ossoli A, Neufeld EB, Thacker SG, Vaisman B, Pryor M, Freeman LA; et al. (2016). "Lipoprotein X Causes Renal Disease in LCAT Deficiency". PLoS One. 11 (2): e0150083. doi:10.1371/journal.pone.0150083. PMC 4769176. PMID 26919698.
- Lynn EG, Siow YL, Frohlich J, Cheung GT, O K (2001). "Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B." Kidney Int. 60 (2): 520–32. doi:10.1046/j.1523-1755.2001.060002520.x. PMID 11473635.
- Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C; et al. (1993). "Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease". J Clin Invest. 91 (2): 677–83. doi:10.1172/JCI116248. PMC 288009. PMID 8432868.
- Gotoda T, Yamada N, Murase T, Sakuma M, Murayama N, Shimano H; et al. (1991). "Differential phenotypic expression by three mutant alleles in familial lecithin:cholesterol acyltransferase deficiency". Lancet. 338 (8770): 778–81. PMID 1681161.
- Naghashpour M, Cualing H (2009). "Splenomegaly with sea-blue histiocytosis, dyslipidemia, and nephropathy in a patient with lecithin-cholesterol acyltransferase deficiency: a clinicopathologic correlation". Metabolism. 58 (10): 1459–64. doi:10.1016/j.metabol.2009.04.033. PMID 19592052.
- "Orphanet: LCAT deficiency".
- Hirano K, Kachi S, Ushida C, Naito M (2004). "Corneal and macular manifestations in a case of deficient lecithin: cholesterol acyltransferase". Jpn J Ophthalmol. 48 (1): 82–4. doi:10.1007/s10384-003-0007-1. PMID 14767661.
- Suda T, Akamatsu A, Nakaya Y, Masuda Y, Desaki J (2002). "Alterations in erythrocyte membrane lipid and its fragility in a patient with familial lecithin:cholesterol acyltrasferase (LCAT) deficiency". J Med Invest. 49 (3–4): 147–55. PMID 12323004.
- Hrycek A, Cieślik P, Trzeciak HI (1994). "[Clinical features of lecithin-cholesterol acyltransferase deficiency]". Przegl Lek. 51 (12): 516–9. PMID 7746888.
- Saeedi R, Li M, Frohlich J (2015). "A review on lecithin:cholesterol acyltransferase deficiency". Clin Biochem. 48 (7–8): 472–5. doi:10.1016/j.clinbiochem.2014.08.014. PMID 25172171.
- Rader DJ, Ikewaki K, Duverger N, Schmidt H, Pritchard H, Frohlich J; et al. (1994). "Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease". J Clin Invest. 93 (1): 321–30. doi:10.1172/JCI116962. PMC 293770. PMID 8282802.
- Schaefer EJ, Anthanont P, Diffenderfer MR, Polisecki E, Asztalos BF (2016). "Diagnosis and treatment of high density lipoprotein deficiency". Prog Cardiovasc Dis. 59 (2): 97–106. doi:10.1016/j.pcad.2016.08.006. PMID 27565770.
- Schaefer EJ, Santos RD, Asztalos BF (2010). "Marked HDL deficiency and premature coronary heart disease". Curr Opin Lipidol. 21 (4): 289–97. doi:10.1097/MOL.0b013e32833c1ef6. PMID 20616715.
- Shamburek RD, Bakker-Arkema R, Auerbach BJ, Krause BR, Homan R, Amar MJ; et al. (2016). "Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement". J Clin Lipidol. 10 (2): 356–67. doi:10.1016/j.jacl.2015.12.007. PMC 4826469. PMID 27055967.
- Simonelli S, Tinti C, Salvini L, Tinti L, Ossoli A, Vitali C; et al. (2013). "Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency". Biologicals. 41 (6): 446–9. doi:10.1016/j.biologicals.2013.09.007. PMID 24140107.
- Aranda P, Valdivielso P, Pisciotta L, Garcia I, Garcã A-Arias C, Bertolini S; et al. (2008). "Therapeutic management of a new case of LCAT deficiency with a multifactorial long-term approach based on high doses of angiotensin II receptor blockers (ARBs)". Clin Nephrol. 69 (3): 213–8. PMID 18397721.
- Ahmad SB, Miller M, Hanish S, Bartlett ST, Hutson W, Barth RN; et al. (2016). "Sequential kidney-liver transplantation from the same living donor for lecithin cholesterol acyl transferase deficiency". Clin Transplant. 30 (10): 1370–1374. doi:10.1111/ctr.12826. PMID 27490864.